Repatha (Evolocumab) Global Regulatory Status
A comprehensive review of Repatha's FDA approval, EMA authorization, label expansions, FOURIER outcomes data, and current regulatory standing across major markets.
Evolocumab: Regulatory History
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
8articles
4topic areas covered
May 26, 2026latest review
Evolocumab: Regulatory History library
Showing 8 of 8 clinical reviews.
Repatha (Evolocumab) Pipeline, FDA History, and Next-Generation PCSK9 Therapies
A clinical review of Repatha's FDA approval history, current label indications, post-market safety data, and emerging next-generation PCSK9-targeting therapies in development.
Repatha (Evolocumab): EMA vs FDA Regulatory Approach
A detailed comparison of how the FDA and EMA have regulated Repatha (evolocumab), including approval timelines, label differences, post-market surveillance, and safety requirements.
Repatha (Evolocumab): Legal and Patent Challenges, FDA History, and Regulatory Field
A clinical review of Repatha's FDA approval history, patent disputes with Sanofi/Regeneron, label updates, post-market safety surveillance, and the regulatory path that shaped PCSK9 inhibitor access.
Repatha Compounding Legal Status: What Patients and Prescribers Need to Know
A comprehensive regulatory guide to evolocumab (Repatha) FDA approval, compounding legal status, label requirements, and safety data for clinicians and patients.
Repatha FAERS Safety Signals: What the FDA Adverse Event Data Actually Shows
A deep review of evolocumab (Repatha) FAERS safety signals, FDA label warnings, post-market surveillance data, and what FOURIER and real-world pharmacovigilance reports mean for patients on PCSK9 inhibitor therapy.
Repatha FDA Approval History: Every Label Change From 2015 to Today
A complete timeline of Repatha (evolocumab) FDA approvals, supplemental indications, boxed-warning updates, and post-market safety data from 2015 through 2026.
Repatha Label Updates 2020 to 2026: Every FDA Change Explained
A full chronological review of every Repatha (evolocumab) FDA label update from 2020 through 2026, including new indications, dosing changes, safety revisions, and what each change means for prescribers and patients.